Market closedNon-fractional

Xilio Therapeutics/XLO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Ticker

XLO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Waltham, United States

Employees

56

XLO Metrics

BasicAdvanced
$38M
Market cap
-
P/E ratio
-$2.57
EPS
-0.04
Beta
-
Dividend rate
$38M
-0.04
2.191
2.026
30.518
34.822
-120.24%
-46.46%
-128.37%
1.36
1.36
-0.52
-21.43%
-71.11%

What the Analysts think about XLO

Analyst Ratings

Majority rating from 3 analysts.
Buy

XLO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$17M
-2.27%
Profit margin
0.00%
NaN%

XLO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 463.64%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.61
-$0.64
-$0.62
-
Expected
-$0.87
-$0.81
-$0.64
-$0.11
-$0.23
Surprise
-19.31%
-24.46%
0.00%
463.64%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Xilio Therapeutics stock?

Xilio Therapeutics (XLO) has a market cap of $38M as of July 14, 2024.

What is the P/E ratio for Xilio Therapeutics stock?

The price to earnings (P/E) ratio for Xilio Therapeutics (XLO) stock is 0 as of July 14, 2024.

Does Xilio Therapeutics stock pay dividends?

No, Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders as of July 14, 2024.

When is the next Xilio Therapeutics dividend payment date?

Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders.

What is the beta indicator for Xilio Therapeutics?

Xilio Therapeutics (XLO) has a beta rating of -0.04. This means that it has an inverse relation to market volatility.

Buy or sell Xilio Therapeutics stock

Buy or sell Xilio Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing